🚀 Medial Secures Investment on Shark Tank India - Fueling the Future of Professional Social Networking. 🔥
Login

News on Medial

Transcell Biologics secures funding from IAN & Quantiphi

EntrackrEntrackr · 1y ago
Transcell Biologics secures funding from IAN & Quantiphi
Medial

Bio-tech company Transcell Biologics has raised an undisclosed amount of investment from Boston-based Quantiphi and IAN Group. The proceeds will be used for expanding the client base and implementation of Digital Animal Replacement Technology (DART) as an enterprise solution for the global bio and pharmaceutical industry, Transcell Biologics said in a press release. Launched in 2009 by Subadra Dravida, Transcell Biologics specializes in maximizing stem cell yield while retaining pluripotency and functionality and also offers a proprietary process and has diversified its applications for stem cell technologies. According to the Hyderabad-based company, DART provides animal-free testing methods, fusing human MicroPhysiological Systems (hMPS) technology with AI/ML embedded in silico platform configurations to streamline and automate the bioassay processes producing statistically compliant reports. The solution is designed to effectively test safety and efficacy concerns surrounding drugs and vaccines meant for human consumption. Transcell Biologics says that implementation of DART has gained significant traction in Indian markets, with biopharmaceutical companies adopting its enterprise solution in their high-impact programs. The company intends to expand its client base in the USA, Europe, and Japan.

Related News

Lamark Biotech raises Rs 6.5 Cr in pre-Series A round led by IAN Group

EntrackrEntrackr · 6m ago
Lamark Biotech raises Rs 6.5 Cr in pre-Series A round led by IAN Group
Medial

Lamark Biotech raises Rs 6.5 Cr in pre-Series A round led by IAN Group Lamark's proprietary ProteoStrong platform enables the stabilization of fragile protein-based drugs, such as insulin, monoclonal antibodies, and enzymes, without altering their molecular structure. Biopharma startup Lamark Biotech has raised Rs 6.5 crore in a pre-Series A round led by IAN Group, including IAN Alpha Fund, powered by BioAngels, Vinayender Tulla, Nita Roy, and Venkataraman KNK. Domain experts from IAN’s angel investors led the round. The Ahmedabad-based company had previously raised $41.3K in a seed funding round led by VIT-TBI and others. The fresh funds will be utilized to accelerate the development of thermostable insulin and expand the biologics platform for global access, Lamark said in a press release. Founded in 2018 by Vaibhav Bhatia, Lamark Biotech aims to reimagine drug delivery for chronic and life-altering diseases. Its proprietary ProteoStrong platform enables the stabilization of fragile protein-based drugs, such as insulin, monoclonal antibodies, and enzymes, without altering their molecular structure. According to Lamark Biotech, it leverages the R&D base of Venture Center, NCL Innovation, and it is advancing a new class of temperature-resilient biologics that retain potency across extreme conditions—ideal for underserved regions where cold storage infrastructure is limited. With its lead program, InsulinStrong, Lamark is targeting the Rs 4,000 crore Indian insulin market and intends to expand across Southeast Asia and the UAE. In the next 24 months, it plans to file new international patents, begin early clinical trials, and build partnerships with pharma companies, CDMOs, and global health agencies.

IAN Group appoints Info Edge’s Chintan Thakkar as Group CEO

EntrackrEntrackr · 4m ago
IAN Group appoints Info Edge’s Chintan Thakkar as Group CEO
Medial

Early stage investment platform IAN Group has appointed Chintan Thakkar as Group CEO of IAN Group. The move comes as part of a broader strategy to augment the Group and build it to fuel future growth. Chintan will also provide critical guidance to the recently launched IAN Alpha Fund as a Senior Managing Partner for the Fund. Formerly the Group CFO & Whole time Director at Info Edge India, Chintan is a seasoned leader in finance, governance, and strategic growth and brings over three decades of experience, vision, and leadership to the IAN Group. At Info Edge, Chintan played a pivotal role in the company’s transformation from a small cap to large cap company with 18x market capitalisation growth, helped execute landmark capital market and M&A transactions, and was deeply involved in the company’s investments in early stage companies as well as in launching AIFs for startup investments. “IAN is one of India’s most respected names in the investment world. Its commitment to investing in innovation that addresses real problems or meets national strategic imperatives truly excites me. I look forward to making a significant contribution alongside the IAN Board and the team,” said Thakkar. IAN enables entrepreneurs to raise from Rs 50 lakhs to Rs 50 crore on a single platform, along with mentoring and global market access. The Group’s investment thesis has been to invest in startups in emerging sectors led by exceptional founders solving real problems or building for India’s strategic imperatives, while giving exceptional investor returns. Over the last 19 years, it claims to have consistently returned capital with multiples in high double digits.

IAN Group marks final close of $100 Mn Alpha Fund

EntrackrEntrackr · 21d ago
IAN Group marks final close of $100 Mn Alpha Fund
Medial

IAN Group marks final close of $100 Mn Alpha Fund Early-stage investment platform IAN Group has completed the final close of its second venture capital vehicle, the IAN Alpha Fund, with a corpus of $100 million. The fund aims to back early-stage, tech-enabled startups addressing major industry and societal challenges. Its investment focus spans sectors such as artificial intelligence, space tech, semiconductors, climate, healthcare, and other frontier domains. The Alpha Fund saw backing from a mix of institutional and government-linked investors, including funds like the Self-Reliant India Fund, SIDBI Fund of Funds for Startups, ACE Fund, and Odisha Startup Growth Fund, along with insurance and family-office investors. According to IAN, several of its initial portfolio companies, 10 to 12 so far, are led by first-generation founders based in tier-II and tier-III cities. IAN enables entrepreneurs to raise from Rs 50 lakhs to Rs 50 crore on a single platform, along with mentoring and global market access. The Group’s investment thesis has been to invest in startups in emerging sectors led by exceptional founders solving real problems or building for India’s strategic imperatives, while giving exceptional investor returns. Over the last 19 years, it claims to have consistently returned capital with multiples in high double digits. The fund follows IAN’s broader vision of supporting startup growth across geographies and sectors, with a stated aim to help founders in smaller cities get the same opportunities as those in major urban centres. In August this year, IAN Group had also appointed Chintan Thakkar as Group CEO of IAN Group.

Download the medial app to read full posts, comements and news.